NVCR Company Profile and Key Details

NovoCure Limited has 111.80 million shares outstanding. The public float is 94.15 million shares, elevated short interest at 7.79% of float. This equals 5.51 million shares. The short ratio is 2.68 days. Institutional investors hold 95.96% of the float. Insiders own 9.88%. DOYLE WILLIAM F holds 551.18 thousand shares, Cordova Ashley has 437.57 thousand shares and GROENHUYSEN WILHELMUS CM has 251.24 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Short-term trend indicators are mixed aligned (SMA20 6.9%, SMA50 14.36%, SMA200 -1.58%). The stock’s 14-day RSI is 61.97 (firm momentum), while the ATR of 0.58 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -49.75% below its high and over 34.11% above its low. Average 10-day trading volume of 1.13 million shares is below the 3-month average of 1.49 million, indicating normal recent market interest.

NovoCure Limited generated EPS of -$1.61 over the past year. Five-year average earnings growth is -83.87%. Wall Street analysts project EPS growth of 11.72% annually over the next five years. The latest quarter delivered EPS of -$0.33. The next quarter is forecast at -$0.40. Next year's EPS is expected at $3.56. Analyst sentiment is neutral. Analyst rating data shows there are 1 Strong Buy ratings, 3 Buy ratings, 3 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $42.00 to $14.50. The high target offers 192.68% upside. The low target suggests 1.05% downside. The mean target is $29.93. This offers 108.57% upside. NovoCure Limited earnings surprise history is frequent misses against expectations. The quarter that ended October 30, 2025, missed forecasts by -20.7%. The prior quarter beat by -7.69%. Over the last six quarters, Apple has recorded several small beats. These include -22.53% in July 25, 2024.

NovoCure Limited last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$5.28. This means the shares are trading below this model’s fair value.

NovoCure Limited (NASDAQ:NVCR) closed at $14.35 USD, losing -$0.52 (-3.50%) from the previous close of $14.87. The stock is currently mid-range between its 52-week high and low $10.70 and $28.13. With a market capitalization of about $1.61 billion, NovoCure Limited is classified as a small-cap and shows lower-than-market volatility (beta ~0.73). Key stats such as the average daily volume over the past year has been around 1.56 million shares, volume is running light vs its 52-week average. Headquartered in Saint Helier, None, NovoCure Limited operates in the Healthcare sector and the Medical - Instruments & Supplies industry. Led by CEO Frank Leonard, the company employs approximately 1,488 people and listed since October 01, 2015. NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China.

Our AI price prediction model suggests that NovoCure Limited stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 6.06%, with price expected at $15.22 by January 23, 2026, within a range of $14.59 to $15.87 3-Month Outlook: Projected fall of -53.52%, reaching $6.67 by April 09, 2026, with a range of $5.46 to $7.45. 1-Year Outlook: Projected gain of 72.82%, with price at $24.80 by December 31, 2026, within a range of $11.87 to $26.76.

NovoCure Limited (NASDAQ:NVCR) shares are up 15.0% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows NovoCure Limited trading at a premium to the broader market with a P/E of -9.04. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $72.70, suggesting 406.62% upside. Our AI forecast model points to short-term strength (6.06% over two weeks), a medium-term fall (-53.52% over three months), and a longer-term gain (72.82% over one year), with expected trading ranges indicating moderate volatility.

NovoCure Limited trades at a P/E ratio of -9.04, slightly below the S&P 500 average, with a price-to-sales ratio of 2.5 and a price-to-book ratio of 4.7 trading at moderately above to book value. The P/FCF stands at -24.66, also below market averages.